lupin-pharmaceuticals Research by SuperAGI

Overview

Lupin Pharmaceuticals is a wholly-owned subsidiary of Lupin Limited, a global leader in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited has a robust international presence, having entered the United States market in 2003. The company is known for its diverse portfolio that includes both branded and generic pharmaceuticals, and it specializes in critical therapeutic areas such as cardiovascular, respiratory, diabetes, neurology, gastrointestinal, and women's health.

Leadership

Lupin's leadership is composed of highly experienced professionals:

Vinita Gupta, Chief Executive Officer: As CEO, Vinita Gupta not only directs the strategic growth and market expansion of Lupin Pharmaceuticals globally but also chairs Lupin Inc. Her leadership has been recognized as one of India's 50 Most Powerful Women in Business by Fortune India.

Nilesh D. Gupta, Managing Director: He manages the company's research, supply chain, and regulatory operations and has been MD since September 2013.

Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus SBU: With three decades in the industry, Ramesh leads the finance strategies and corporate affairs.

Manju D. Gupta, Chairman (Non-Executive): With a longstanding role in Lupin's governance, she sustains its corporate strategies.

Product Portfolio and Innovation

Lupin is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs) and serves over 70 countries. In the United States, Lupin Pharmaceuticals, Inc. markets over 185 drugs. Lupin's achievements in research and development include 437 ANDA filings with 289 approvals, underscoring its dedication to affordable and high-quality pharmaceutical solutions.

Financial Highlights

Lupin is publicly traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) under the ticker BOM:500257, with a share price around INR 2154.60. The company plans to raise Rs 7500 crore for strategic acquisitions, aligning with its growth ambitions.

Global Reach

With operations in 11 countries, Lupin employs more than 20,000 people and offers its products in over 100 markets, showcasing its ability to provide medicines effectively on a global scale.

Recent Developments and Accolades

Lupin has been recognized for its innovation and corporate social responsibility through awards such as:

Champions of ESG Award at the ESG Impact Summit 2024.

Patient-Centric Pharmaceutical Company of the Year at the IHW 3rd Patient First Awards 2024.

Additionally, the company received US FDA clearance for its Pithampur manufacturing facility, enhancing its compliance credentials.

Competitor Profiling

As a key player, Lupin faces competition in the generic and specialty drug markets. However, it continues to excel through strategic innovation and comprehensive research and development efforts. The company's focus on biosimilars and complex generics highlights its capacity to fulfill unmet medical needs while preserving competitive advantage.

Strategic Initiatives

Lupin is strategically expanding its international presence, particularly in emerging markets, through acquisitions and a commitment to regulatory compliance. By investing in respiratory and neurology products, as well as developing complex generics and biosimilars, Lupin is poised to capture emerging opportunities and expand its market share.

Key Executive: Dr. Vinita Gupta

As the CEO, Dr. Vinita Gupta's strategic direction is vital for Lupin's global market presence and sustained profitability. Her experience and focus on strategic collaborations have bolstered Lupin's competitive edge, contributing significantly to the company's international success.

Professional Achievements

Under her leadership, Lupin has launched numerous high-value generics and solidified its specialty drug segment. Dr. Gupta's proficiency in navigating complex markets and fostering strategic partnerships remains critical to Lupin's success.